mankhwala osakhala ang'onoang'ono a khansa ya m'mapapo

Khansara ya m'mapapo yosakhala yaying'ono (NSCLC) ndi mtundu wamba wa khansa ya m'mapapo. Njira zochizira za NSCLC ndizosiyanasiyana ndipo zimadalira zinthu zingapo, kuphatikiza gawo la khansa, thanzi la wodwalayo, komanso kusintha kwa majini mkati mwa chotupacho. Bukhuli likupereka chithunzithunzi cha njira zazikulu zothandizira NSCLC, kuyambira opaleshoni ndi chithandizo cha radiation kupita ku chithandizo chamankhwala cholunjika ndi immunotherapy, kupatsa mphamvu odwala ndi osamalira ndi chidziwitso chopanga zisankho zoyenera.Khansara ya m'mapapo yosakhala yaying'ono (NSCLC) ndi gulu la khansa ya m'mapapo yomwe imachita chimodzimodzi. Mitundu yayikulu ya NSCLC ndi adenocarcinoma, squamous cell carcinoma, ndi cell carcinoma yayikulu. Kuzindikira kolondola, kuphatikiza kuyesa kwa ma cell ndi ma cell, ndikofunikira kuti mudziwe njira yabwino kwambiri yothandizira. Shandong Baofa Cancer Research Institute yadzipereka ku kafukufuku wa khansa ndi chitukuko cha njira zatsopano zothandizira, phunzirani zambiri pa https://baofahospital.com.Staging ya NSCLCNSCLC imayendetsedwa pogwiritsa ntchito TNM system (Tumor, Node, Metastasis). Gawoli limafotokoza kukula ndi malo a chotupa chachikulu (T), ngati khansa yafalikira ku ma lymph nodes (N), komanso ngati khansayo yafalikira kumadera akutali (M). Magawo amachokera ku I (oyambirira) mpaka IV (siteji yapamwamba). Mayeso a Molecular a NSCLCMayeso a molekyulu amazindikiritsa kusintha kwa majini kapena kusokonezeka kwa mapuloteni mkati mwa maselo otupa. Ma biomarkers awa atha kuthandizira kudziwa ngati wodwala ali woyenera kulandira chithandizo chomwe akufuna. Kusintha kofala kumaphatikizapo EGFR, ALK, ROS1, BRAF, ndi ena. Zotsatira za kuyesa kwa maselo zimakhudza kwambiri zisankho za chithandizo.Standard Chithandizo cha NSCLCOpaleshoniOpaleshoni nthawi zambiri ndiyo njira yoyamba yothandizira ya NSCLC yoyambirira (magawo I ndi II). Cholinga chake ndi kuchotsa chotupacho ndi ma lymph nodes apafupi. Mitundu ya opaleshoni ndi: Kuchotsa Wedge: Kuchotsa kachidutswa kakang'ono ka m'mapapo. Segmentectomy: Kuchotsa gawo lalikulu la mapapo kuposa mphero. Lobectomy: Kuchotsa lobe lonse la mapapo. Iyi ndiye njira yodziwika kwambiri ya opaleshoni ya NSCLC. Pneumonectomy: Kuchotsa mapapo onse. Izi sizofala kwambiri ndipo zimasungidwa ku zotupa zambiri.Radiation TherapyRadiation therapy imagwiritsa ntchito kuwala kwamphamvu kwambiri kupha maselo a khansa. Itha kugwiritsidwa ntchito ngati chithandizo choyambirira, pambuyo pa opaleshoni kupha maselo a khansa omwe atsala, kapena kuchepetsa zizindikiro (palliative radiation). Mitundu yosiyanasiyana ya ma radiation therapy ndi awa: External Beam Radiation Therapy (EBRT): Ma radiation amaperekedwa kuchokera ku makina kunja kwa thupi. Stereotactic Body Radiation Therapy (SBRT): Amapereka ma radiation ochuluka kudera laling'ono, lomwe amalifuna ndendende. Nthawi zambiri amagwiritsidwa ntchito poyambira NSCLC pomwe opaleshoni sichitha. Brachytherapy (Internal Radiation Therapy): Zinthu zopangira radioactive zimayikidwa mwachindunji mkati mwa chotupacho kapena pafupi nacho.ChemotherapyChemotherapy imagwiritsa ntchito mankhwala kupha maselo a khansa mthupi lonse. Nthawi zambiri amagwiritsidwa ntchito limodzi ndi opaleshoni kapena ma radiation therapy, kapena ngati chithandizo choyambirira chapamwamba Mtengo wa NSCLC. Mankhwala odziwika bwino a chemotherapy a NSCLC ndi monga cisplatin, carboplatin, paclitaxel, docetaxel, pemetrexed, ndi gemcitabine.Targeted Therapy for Chithandizo cha NSCLCMankhwala omwe akuyembekezeredwa ndi mankhwala omwe amayang'ana mamolekyu ena omwe amakhudzidwa ndi kukula kwa maselo a khansa ndi kupulumuka. Njira zochiritsirazi zimakhala zogwira mtima ngati chotupacho chili ndi kusintha kwachibadwa kwachibadwa kapena kusokonekera kwa mapuloteni.EGFR InhibitorsEGFR (epidermal growth factor receptor) inhibitors amagwiritsidwa ntchito pochiza. Mtengo wa NSCLC ndi kusintha kwa EGFR. Mankhwalawa amaletsa mapuloteni a EGFR, omwe amathandiza maselo a khansa kukula. Zitsanzo ndi izi: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso)ALK InhibitorsALK (anaplastic lymphoma kinase) inhibitors amagwiritsidwa ntchito pochiza. Mtengo wa NSCLC ndi ALK gene rearrangements. Mankhwalawa amaletsa mapuloteni a ALK, omwe amathandiza maselo a khansa kukula. Zitsanzo ndi izi: Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena)ROS1 InhibitorsROS1 inhibitors amagwiritsidwa ntchito pochiza Mtengo wa NSCLC ndi ROS1 gene rearrangements. Mankhwalawa amaletsa mapuloteni a ROS1, omwe amathandiza maselo a khansa kukula. Zitsanzo ndi izi: Crizotinib (Xalkori) Entrectinib (Rozlytrek)BRAF InhibitorsBRAF inhibitors amagwiritsidwa ntchito pochiza. Mtengo wa NSCLC ndi kusintha kwa BRAF V600E. Mankhwalawa amalepheretsa mapuloteni a BRAF. Zitsanzo ndi izi: Dabrafenib (Tafinlar) Trametinib (Mekinist) (yomwe imagwiritsidwa ntchito limodzi ndi Dabrafenib)Machiritso Ena Omwe AkuwafuniraNjira zochiritsira zomwe zimayang'aniridwa zingagwiritsidwe ntchito malingana ndi masinthidwe enieni omwe amapezeka mu chotupacho. Zitsanzo zikuphatikizapo RET inhibitors (za RET fusions) ndi MET inhibitors (for MET exon 14 skipping mutations) . Chithandizo cha NSCLCMankhwala a Immunotherapy amathandiza chitetezo cha mthupi kulimbana ndi khansa. Amagwira ntchito potsekereza mapuloteni omwe amalepheretsa chitetezo chamthupi kuukira maselo a khansa. Izi zimagwiritsidwa ntchito nthawi zambiri Mtengo wa NSCLC chithandizo.PD-1/PD-L1 InhibitorsPD-1 (protein ya kufa kwa maselo 1) ndi PD-L1 (programmed death-ligand 1) inhibitors amalepheretsa njira ya PD-1 / PD-L1, yomwe imathandiza maselo a khansa kuthawa chitetezo cha mthupi. Zitsanzo ndi izi: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo)CTLA-4 InhibitorsCTLA-4 (cytotoxic T-lymphocyte-associated protein 4) imathandizira chitetezo cha mthupi kuletsa ma cell a khansa, CTLA-4 inhibitors. Chitsanzo ndi Ipilimumab (Yervoy), yomwe nthawi zambiri imagwiritsidwa ntchito pamodzi ndi PD-1 inhibitors.Kuphatikiza Mankhwala OchiritsiraKawirikawiri, Chithandizo cha NSCLC kuphatikizika kwa machiritso osiyanasiyana. Mwachitsanzo, opaleshoni imatha kutsatiridwa ndi chemotherapy kapena radiation therapy. Thandizo lokhazikika kapena immunotherapy lingaphatikizidwe ndi chemotherapy. Kuphatikiza kwapadera kudzadalira momwe wodwalayo alili. Kuti mudziwe zambiri za kafukufuku wa khansa pitani Shandong Baofa Cancer Research Institute.Clinical TrialsClinical mayesero ndi kafukufuku amene amawunika mankhwala atsopano kapena kusakanizidwa kwamankhwala. Odwala ndi Mtengo wa NSCLC angalingalire kutenga nawo mbali m'mayesero azachipatala kuti apeze chithandizo chamakono. Zambiri zokhudzana ndi mayeso azachipatala zitha kupezeka patsamba la National Cancer Institute ndi malo ena odziwika bwino.Side Effect ManagementAll Chithandizo cha NSCLC zingayambitse mavuto. Ndikofunikira kukambirana ndi dokotala za zotsatira zoyipa zomwe zingachitike ndikuphunzira momwe mungathanirane nazo. Chisamaliro chothandizira, monga kuchepetsa ululu ndi chithandizo cha zakudya, kungathandize kusintha moyo pa nthawi ya chithandizo.Prognosis and Follow-Up CareThe prognosis for Mtengo wa NSCLC zimadalira pa siteji ya khansayo, thanzi lonse la wodwalayo, ndi momwe khansayo imachitira ndi chithandizo. Kusankhidwa kotsatira nthawi zonse n'kofunika kuti muyang'ane kuti mubwererenso ndikuwongolera zotsatira za nthawi yayitali za chithandizo.Chodzikanira: Nkhaniyi ikupereka zambiri za Chithandizo cha khansa ya m'mapapo yaing'ono (NSCLC). ndipo sayenera kutengedwa ngati upangiri wamankhwala. Nthawi zonse funsani dokotala wanu kapena katswiri wina wodziwa zachipatala kuti akupatseni malingaliro anu okhudzana ndi matenda anu enieni.